Nimbus therapeutics announces closing of takeda's acquisition of tyk2 subsidiary

Boston--(business wire)--nimbus therapeutics, llc (“nimbus therapeutics” or “nimbus”), a clinical-stage company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, today announced the closing of takeda's (tse:4502/nyse:tak) acquisition of nimbus lakshmi, inc., a wholly-owned subsidiary of nimbus, and its tyrosine kinase 2 (tyk2) inhibitor program, which includes the oral, selective allosteric tyk2 inhibitor ndi-034858, now known as tak-279.
TAK Ratings Summary
TAK Quant Ranking